QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) announced today that its subsidiary, Ortho Clinical Diagnostics, a leading provider of in vitro diagnostics solutions and services to hospitals, clinical laboratories and blood banks around the world, has earned the No. 1 ranking in the diagnostics industry for Overall Customer Satisfaction in the 2022 IMV ServiceTrak™ Awards for the fifth consecutive year. The ranking is based on interviews conducted with laboratory professionals, including Ortho’s customers, from more than 1,200 clinical testing locations operating over 1,900 collective instruments. The prestigious annual IMV ServiceTrak™ Awards rankings affirm the continued power and impact of Ortho’s innovative Ortho Care® Services and Informatics platform.
McMaster University researchers behind a new form of rapid, accurate and portable diagnostic test are moving their work toward the marketplace.
SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications.
Engineering, biochemistry and medical researchers from McMaster University have created a hand-held rapid test for bacterial infections that can produce accurate, reliable results in less than an hour, eliminating the need to send samples to a lab.
To improve the development of new saliva-based diagnostic tests and personalized medicine, the National Institute of Dental and Craniofacial Research (NIDCR) has supported the development of the Human Salivary Proteome Wiki, the first public platform that catalogs and curates data on each of the thousands of proteins within our saliva.
A new grant is helping McMaster University engineers and a Toronto precision-medicine diagnostics company to get infection-testing technology to market while generating opportunities for students.
Sysmex America, Inc., a leading diagnostic solutions company offering hematology, urinalysis, information systems and flow cytometry testing technology for optimal clinical laboratory performance, will be exhibiting virtually at the 72nd AACC Annual Scientific Meeting & Clinical Lab Expo, December 14 – 17.
In the wake of the novel coronavirus pandemic, the need for reliable, accurate, and accessible laboratory testing is more evident than ever before. At the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory medicine experts will present the cutting-edge research and technology that is revolutionizing clinical testing and patient care for COVID-19 and across the spectrum of healthcare.
Baebies has been named a finalist for the 2020 American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award for FINDER®, a near-patient testing platform. As a growth-stage company developing diagnostic products to provide a healthy start for children everywhere, Baebies FINDER tests for diseases from low blood volume (50 µL) with a turn-around time of approximately 15 minutes after sample introduction.
Curbing the coronavirus pandemic relies heavily on how quickly a potentially exposed individual can be tested and quarantined. However, the current diagnostic techniques vary in reliability and relevance, so an understanding of which test is most appropriate for a given circumstance is necessary to avoid false reports. Researchers evaluated the available diagnostic techniques and determined key steps required for better testing moving forward. They present their findings in the journal APL Bioengineering.
NIH, with BARDA, today announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new competition that will support cutting-edge research that could significantly improve diagnostic testing and patient care. Winners of the competition will each receive a sample set from AACC’s Universal Sample Bank, which includes blood samples from hundreds of healthy individuals that were collected to aid medical studies.
AACC has issued a new guidance document detailing best practices that hospitals and other healthcare institutions should follow when running a point-of-care testing program. As point-of-care tests emerge for more and more conditions—including COVID-19—the guidance emphasizes that it is essential for laboratory professionals and clinicians to collaborate on point-of-care testing programs to ensure this testing benefits patients.
The David Eccles School of Business at the University of Utah and University of Utah Health announce the start of Utah HERO (Health & Economic Recovery Outreach), a massive undertaking that will begin with the testing of 10,000 Utahns across four counties. The data gathered will inform decision-makers in the state as they work to help keep residents safe and get people back to work.
NIH today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2020 AACC and AACC Academy Awards. Through this annual awards program, AACC and its academy recognize individuals worldwide for exceptional research and service in the field of laboratory medicine, and strive to raise awareness that clinical laboratory testing is vital to quality patient care.
AACC is pleased to announce that the organization will be able to preserve the complete 2020 AACC Annual Scientific Meeting & Clinical Lab Expo experience for its attendees by moving the meeting to December 13-17, 2020. After carefully monitoring the ongoing global crisis caused by the COVID-19 outbreak, the association’s leadership determined that rescheduling is the best way to safeguard the health of meeting attendees, partners, and staff, which is AACC’s number one priority.
On March 5, U.S. House and Senate lawmakers introduced the VALID Act, which would give the Food and Drug Administration (FDA) new, expansive powers to regulate laboratory developed tests—tests that are already regulated by the Centers for Medicare and Medicaid Services (CMS) and are subject to stringent personnel, quality control, and proficiency testing requirements. This bill promotes duplicative, costly federal regulations for clinical laboratories that will result in decreased patient access to essential medical tests. AACC urges Congress not to act on this bill until its impact on healthcare can be thoroughly evaluated.
AACC thanks the FDA for being responsive to the concerns of the clinical laboratory community and amending the coronavirus guidance to allow CMS-certified labs to develop and implement new tests for coronavirus prior to FDA approval.
In a letter to the Food and Drug Administration (FDA), AACC is urging the agency to allow clinical laboratories to develop coronavirus tests without going through FDA review. Lifting this regulatory requirement is key to ensuring that all patients have access to high-quality coronavirus testing and that healthcare workers have the tools they need to control the spread of this disease in the U.S.
Breaking research in AACC’s Clinical Chemistry journal shows that two new tests accurately diagnose coronavirus infection in about 1 hour. These tests could play a critical role in halting this deadly outbreak by enabling healthcare workers to isolate and treat patients much faster than is currently possible.
A new study by Carey Business School researchers notes that some expert medical diagnosticians may order fewer patient tests as a way to indicate a high level of competence to their peers. They do so despite an increase in diagnostic techniques that can assess patient condition more accurately than former methods.
A newly developed method can detect even low-dose human exposure to microcystins and nodularin in human urine. During harmful algal blooms (HABs), species of cyanobacteria release toxic peptides, including microcystins and nodularin into waterways, impacting wildlife and humans living in these marine environments. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida, and is a critical step in developing and interpreting clinical diagnostic tests for HABs exposure worldwide.
Biotin’s upsurge in popularity has led to a parallel rise in incidents of this health supplement interfering with critical medical tests. A new guidance document from AACC urges clinicians and laboratory experts to collaborate to prevent this potentially harmful test interference, and to ensure that patients taking biotin receive high quality care.
Researchers reporting in ACS Nano have devised a blood test that quickly and sensitively diagnoses the disease at early stages.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that its peer-reviewed publication The Journal of Applied Laboratory Medicine has been accepted for indexing in PubMed, one of the largest and most respected databases of medical research in the world.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a publishing partnership with Oxford University Press for its peer-reviewed journals, Clinical Chemistry and The Journal of Applied Laboratory Medicine. Both journals will join Oxford University Press’s world-class science portfolio starting in January 2020. The partnership will increase researchers’ and healthcare practitioners’ access worldwide to the important science published in the journals.